009300.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a strong liquidity position, with a current ratio of 9.78, indicating that it holds significantly more current assets than current liabilities. This is supported by a free cash flow of 11,086,114,320 KRW and a cash and equivalents balance of 6,580,472,210 KRW. However, the company has a negative net cash position after subtracting total debt, which may signal potential liquidity risk.
Profitability metrics show a return on equity of 5.67% and a return on assets of 5.24%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The operating margin, calculated as operating income of 10,978,941,150 KRW divided by revenue of 77,799,035,970 KRW, is approximately 14.12%. This is in line with the industry's median operating margin of 15-20%, suggesting the company is performing at the lower end of the industry benchmark.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks, particularly if demand for its products fluctuates in its primary market.
The company's growth trajectory appears stable, with a free cash flow of 11,086,114,320 KRW and a capital expenditure of -1,778,532,310 KRW, indicating a net outflow for investment in operations. While the company is not currently experiencing dilution risk, the potential for future dilution remains low, as the number of shares outstanding is the same for both basic and diluted shares.
The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. However, the negative net cash position after subtracting total debt is a key flag that may require further monitoring. The company's debt-to-equity ratio of 0.03 is low, suggesting a conservative capital structure.
Recent financial filings and transcripts do not indicate any major events or strategic shifts. The company's financial performance remains consistent with its historical trends, with no significant changes in its operating or financial structure reported in the latest available data.
- The company has a strong liquidity position with a current ratio of 9.78 and a free cash flow of 11,086,114,320 KRW.
- Profitability metrics are below the industry median, with a return on equity of 5.67% and a return on assets of 5.24%.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company has a low dilution risk, with no difference between basic and diluted shares outstanding.
- The company faces a medium liquidity risk due to a negative net cash position after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 009300.KQ Market data — financials · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Pharmaceuticalsmedium
- Economic sector— → Healthcaremedium